400-859-2883
Your location:Home >News center >Industry News

Industry News

01-132023

2022 FDA Approval & Potencial Blockbu…

FDA approved 37 novel drugs IN 2022, lets find the potencial blockbusters.

2022 FDA Approval & Potencial Blockbusters
10-272022

Top 2 Targets of ADC: HER2 & Trop2

HER2 and Trop2 are the most widely used targets for ADC drugs.

Top 2 Targets of ADC: HER2 & Trop2
10-202022

PEG Hydrogels in Medical Devices

Hydrogels made of PEG materials are also widely used in the field of medical devices.

PEG Hydrogels in Medical Devices
09-212022

Bispecific Antibodies – Fast Growing The…

What are bispecific antibodies, how do they work and how many bispecific antibodies are approved.

Bispecific Antibodies – Fast Growing Therapies
08-192022

Trodelvy: Any Chance Against Dato-DXd and…

Here, we will discuss what are the advantages of Trodelvy, and which is superior in the field of breast cancer treatment, Trodelvy vs. Dato-DXd, Enhertu?

Trodelvy: Any Chance Against Dato-DXd and Enhertu?
07-212022

Approved Antibody–Drug Conjugates (ADCs)…

Approved ADC drugs list and the ongoing trails with hot ADC targets such as HER2, EGFR, TROP2, FRα, CLDN18.2,, c-Met, Nectin-4.

Approved Antibody–Drug Conjugates (ADCs) and In Clinical Trials
07-072022

Lipid-Based Nanoparticles: Liposomes VS. …

Liposomes and Lipid nanoparticles (LNPs) are similar ─ and both can be effective for drug delivery ─ but are different in composition and function.

Lipid-Based Nanoparticles: Liposomes VS. Lipid nanoparticles (LNPs)
05-112022

Lipid Nanoparticles (LNP) for mRNA Drug D…

Lipid Nanoparticle (LNP) is currently the dominant mRNA Drug delivery system.

Lipid Nanoparticles (LNP) for mRNA Drug Delivery
04-192022

New FDA Approved Drugs in Q1 2022

With the first three months of 2022 now in the rear-view mirror, the FDA has approved 10 new drugs (Table 1).

New FDA Approved Drugs in Q1 2022
11-302021

Sitagliptin - First In Class DPP4 Inhibit…

Sitagliptin, the first oral DPP-4 inhibitor to be marketed for treating Type 2 Diabetes

Sitagliptin - First In Class DPP4 Inhibitor for Type 2 Diabetes